On February 2, 2026, Simcere Pharmaceutical Group (2096.HK) announced that its thrombolytic candidate drug for stroke, SIM0811, has recently initiated...

•Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. • Li...

January 20 2026， Simcere Zaiming, an oncology-focused bipharmaceutical company and a subsidiary of Simcere Pharmaceutical Group (2096.HK) announced to...

Jan. 12, 2026， Simcere Pharmaceutical Group (2096.HK) announced positive topline results from a Phase III clinical trial evaluating zemprociti...